SomnusNooze

The First Multi-Site Clinical Trial for IH and Type 2 Narcolepsy in the US Is Underway

ARISE 201 is the first double-blind, placebo-controlled, crossover, multicenter study of a drug (BTD-001) for the treatment of idiopathic hypersomnia (IH) and type 2 narcolepsy (T2N) in adults.

More than 20 study sites throughout the United States are currently prescreening or screening people with IH and T2N for enrollment, with some sites already having enrolled participants. Additional sites are on target to begin enrolling participants in the coming months.

If you are interested in finding out more about this study, please visit http://www.arisestudies.com/ or click on this link to the study on clinicaltrials.gov (https://clinicaltrials.gov/ct2/show/NCT02512588).

 arise

Share Post

SomnusNooze Home Page

SomnusNooze Editions/Archives
Disclaimer

The contents of this website, including text, graphics and other material, are for informational purposes only. This website is not intended to be a substitute for professional legal or medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Always consult your own attorney or other legal advisor with any legal questions you may have. The Hypersomnia Foundation does not recommend or endorse any specific tests, physicians, lawyers, legal advisors, products, procedures, opinions or other information referenced on this website. Reliance on any information on this website is solely at your own risk.

The Hypersomnia Foundation makes no representations or warranties about the satisfaction of any government regulations requiring disclosure of information on prescription drug products. In no event shall The Hypersomnia Foundation be liable for any damages (including without limitation incidental and consequential damages) or costs (including without limitation attorney’s fees) based on any claim arising from the use of this website and/or its content.